Patents by Inventor Samir D. Roy

Samir D. Roy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenazopyridine Compounds
    Publication number: 20130040917
    Abstract: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.
    Type: Application
    Filed: September 14, 2012
    Publication date: February 14, 2013
    Applicant: Pinnacle Pharmaceuticals, Inc.
    Inventors: Sidney HECHT, Nour Eddine Fahmi, Samir D. Roy, George Bonneville
  • Phenazopyridine compounds
    Patent number: 8288365
    Abstract: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: October 16, 2012
    Assignee: Pinnacle Pharmaceuticals, Inc.
    Inventors: Sidney Hecht, Nour Eddine Fahmi, Samir D. Roy, George Bonneville
  • Phenazopyridine Compounds
    Publication number: 20110319367
    Abstract: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.
    Type: Application
    Filed: January 26, 2011
    Publication date: December 29, 2011
    Applicant: Pinnacle Pharmaceuticals, Inc.
    Inventors: Sidney Hecht, Nour Eddine Fahmi, Samir D. Roy, George Bonneville
  • Phenazopyridine compounds
    Patent number: 7893042
    Abstract: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: February 22, 2011
    Assignee: Pinnacle Pharmaceuticals, Inc.
    Inventors: Sidney Hecht, Nour Eddine Fahmi, Samir D. Roy, George Bonneville
  • PHENAZOPYRIDINE COMPOUNDS
    Publication number: 20100204185
    Abstract: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.
    Type: Application
    Filed: December 22, 2009
    Publication date: August 12, 2010
    Applicant: Pinnacle Pharmaceuticals, Inc.
    Inventors: Sidney HECHT, Nour Eddine Fahmi, Samir D. Roy, George Bonneville
  • Laminated composite for transdermal administration of fentanyl
    Patent number: 5186939
    Abstract: A laminated composite for administering fentanyl transdermally that consists of a fentanyl-impermeable occlusive backing layer and an adhesive fentanyl reservoir layer comprising fentanyl dissolved in an amine-resistant polydimethylsiloxane that has a high diffusivity and poor solubility for fentanyl which enables the fentanyl to be released rapidly from the composite over a one day period with little residual fentanyl left in the reservoir thereafter.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: February 16, 1993
    Assignee: Cygnus Therapeutic Systems
    Inventors: Gary W. Cleary, Samir D. Roy
  • Transdermal administration of buprenorphine
    Patent number: 5069909
    Abstract: Method and laminated composite for administering buprenorphine transdermally to treat pain. The composite comprises an impermeable backing layer and a reservoir layer containing buprenorphine and optionally a permeation enhancer combined with a pressure-sensitive adhesive with the amounts of buprenorphine and optional enhancer being sufficient to cause the buprenorphine to pass through the skin at a rate in excess of about 0.05 mcg/cm.sup.2 /hr.
    Type: Grant
    Filed: June 20, 1990
    Date of Patent: December 3, 1991
    Assignee: Cygnus Therapeutic Systems
    Inventors: Kuldeepak Sharma, Samir D. Roy, Eric J. Roos